The Medical University of South Carolina/Hollings Cancer Center (MUSC/HCC) was established as a Minority Underserved site in 2014 to expand and enhance the NCORP trial portfolio by accruing racially/ethnically diverse patients and those from other medically underserved groups into NCORP studies, share expertise and experience on minority recruitment and retention and cultural diversity within the NCORP community, and contribute to the development and implementation of cancer care and cancer delivery research. During the current project period, the MUSC NCORP-MU, which is comprised of two MUSC/HCC sub-affiliates and five community oncology primary affiliates, has made significant contributions to the NCORP program through the effective and efficient accrual of diverse patient populations and leadership that has shaped the scientific agenda for clinical trials, cancer health disparities, and cancer care delivery research. These accomplishments were made possible through a highly invested and transdisciplinary investigative team consisting of Chanita Hughes-Halbert, PhD (Psychiatry & Behavioral Sciences), Marvella E. Ford, PhD (Public Health Sciences), Carolyn D. Britten, MD (Medical Oncology), and David T. Marshall, MD (Radiation Oncology) that has worked hand-in- hand with the clinical research operational leaders at the MUSC/HCC to establish and manage a robust clinical research operation to add value to NCORP. This leadership team has also worked collaboratively with other committed clinical and cancer control researchers, oncology care providers, cancer patients, and survivors in our catchment areas to advance all types of cancer research through the NCORP research bases. The MUSC NCORP-MU aims to improve equity and access to clinical research among racial/ethnic minorities and other medically underserved groups in order to improve cancer outcomes, enhance the quality of cancer care delivery, and reduce cancer health disparities within South Carolina and communities across the US.

Public Health Relevance

Continuation of the Medical University of South Carolina NCORP Minority/Underserved Community Site will provide greater emphasis and availability for residents and healthcare providers of South Carolina to participate in cancer prevention and control, screening, post treatment surveillance, cancer care delivery, treatment, and imaging research studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189848-07
Application #
9993300
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
St Germain, Diane
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Psychiatry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29407
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Ravandi, Farhad; Othus, Megan; O'Brien, Susan M et al. (2016) US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv 1:250-259
Ben-Josef, Edgar; Guthrie, Katherine A; El-Khoueiry, Anthony B et al. (2015) SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol 33:2617-22